We’re excited to announce that Mecwins is playing a pivotal role in IMPACT-Photonics, a revolutionary research project with the potential to transform how we monitor cancer drug treatments in vitro. This initiative brings together leading innovators in photonics, biosensing, and biomedical technology, including Microliquid SL, Bioherent SL, AtG Therapeutics SL, AG Photonics SL, and LEAPWAVE Technologies SL.
The project, officially titled “Research for the Integration of Novel Multiplexed Photonic and Hyperspectral Terahertz Sensing Architectures in a Microfluidic In-Vitro System for Monitoring Cancer Drug Treatments,” is dealing with a crucial challenge: developing more precise and efficient methods for assessing the effectiveness of cancer therapies. Integrated photonic and terahertz systems offer a game-changing approach to healthcare. They enable the creation of compact, cost-effective devices for detecting and monitoring biomarkers with incredible sensitivity.
As part of our activities, we recently received a state-of-the-art photonics chip from Bioherent, and our team is now focused on functionalizing it. This is a critical step towards validating its use in biomedical applications. We’re focused on immobilizing an antibody over the waveguides, which could open doors to highly sensitive biomolecular detection using photonic sensors. Imagine being able to personalize cancer treatment based on real-time monitoring of a patient’s response to drugs. IMPACT-Photonics is working towards making that a reality. The project aims to deliver a prototype photonic chip sensor integrated with microfluidics and chemical functionalization for simultaneous in vitro detection of cancer-related biomarkers. This system, combined with a reading instrument and terahertz spectroscopy, offers several key advantages: detecting extremely low biomarker concentrations that other methods miss; rapid, simultaneous detection of multiple biomarkers from a single patient sample; enhanced therapeutic precision through terahertz reflectometer integration; and personalized patient follow-up through simultaneous monitoring of various biomarkers.
IMPACT-Photonics is also fostering a strong integrated photonics ecosystem in Spain, bringing together companies and research institutions with expertise in all aspects of photonic sensing, from component design to clinical applications. We’re excited to be part of this transformative project and will keep you updated on our progress. Stay tuned!
